全文获取类型
收费全文 | 2350篇 |
免费 | 104篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 59篇 |
妇产科学 | 10篇 |
基础医学 | 230篇 |
口腔科学 | 25篇 |
临床医学 | 455篇 |
内科学 | 359篇 |
皮肤病学 | 11篇 |
神经病学 | 483篇 |
特种医学 | 113篇 |
外科学 | 354篇 |
综合类 | 9篇 |
预防医学 | 87篇 |
眼科学 | 12篇 |
药学 | 95篇 |
中国医学 | 8篇 |
肿瘤学 | 122篇 |
出版年
2022年 | 11篇 |
2021年 | 29篇 |
2020年 | 18篇 |
2019年 | 20篇 |
2018年 | 32篇 |
2017年 | 54篇 |
2016年 | 52篇 |
2015年 | 67篇 |
2014年 | 70篇 |
2013年 | 94篇 |
2012年 | 127篇 |
2011年 | 134篇 |
2010年 | 78篇 |
2009年 | 79篇 |
2008年 | 134篇 |
2007年 | 121篇 |
2006年 | 110篇 |
2005年 | 131篇 |
2004年 | 103篇 |
2003年 | 82篇 |
2002年 | 86篇 |
2001年 | 92篇 |
2000年 | 73篇 |
1999年 | 57篇 |
1998年 | 17篇 |
1997年 | 16篇 |
1996年 | 15篇 |
1993年 | 12篇 |
1992年 | 48篇 |
1991年 | 37篇 |
1990年 | 38篇 |
1989年 | 38篇 |
1988年 | 33篇 |
1987年 | 33篇 |
1986年 | 28篇 |
1985年 | 26篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 10篇 |
1980年 | 10篇 |
1979年 | 15篇 |
1978年 | 12篇 |
1977年 | 10篇 |
1974年 | 12篇 |
1973年 | 10篇 |
1971年 | 9篇 |
1970年 | 12篇 |
1968年 | 12篇 |
1967年 | 9篇 |
1965年 | 13篇 |
排序方式: 共有2461条查询结果,搜索用时 15 毫秒
91.
Image-guided ablation of painful metastatic bone tumors: a new and effective approach to a difficult problem 总被引:1,自引:0,他引:1
Callstrom MR Charboneau JW Goetz MP Rubin J Atwell TD Farrell MA Welch TJ Maus TP 《Skeletal radiology》2006,35(1):1-15
Painful skeletal metastases are a common problem in cancer patients. Although external beam radiation therapy is the current
standard of care for cancer patients who present with localized bone pain, 20–30% of patients treated with this modality do
not experience pain relief, and few further options exist for these patients. For many patients with painful metastatic skeletal
disease, analgesics remain the only alternative treatment option. Recently, image-guided percutaneous methods of tumor destruction
have proven effective for treatment of this difficult problem. This review describes the application, limitations, and effectiveness
of percutaneous ablative methods including ethanol, methyl methacrylate, laser-induced interstitial thermotherapy (LITT),
cryoablation, and percutaneous radiofrequency ablation (RFA) for palliation of painful skeletal metastases. 相似文献
92.
93.
94.
Pascal A. T. Baltzer MD Matthias Benndorf Mieczyslaw Gajda MD Werner A. Kaiser MD 《The breast journal》2010,16(2):197-198
Abstract: Magnetic resonance‐mammography is regarded as the most sensitive diagnostic modality in the detection of breast cancer. It uses the tumour neoangiogenesis to depict lesions after intravenous contrast agent injection. It is said, that for tumours exceeding a diameter of three millimetres contrast agent enhancement is mandatory. In our case report we describe a rare tumour growth condition. We observed a large invasive carcinoma (18 millimetres diameter) without contrast enhancement in breast MRI due to an almost missing tumour neoangiogenesis. The cancer had a low cellularity and a strong desmoplastic reaction. 相似文献
95.
96.
97.
P. Goetz 《Phytothérapie》2017,15(6):320-323
We proposed the subject for the treatment of urinary tract infection and presented at the Phyt’arom Symposium of Grasse 2017, and this in the light of the latest concepts concerning the mode of treatment of an infection, that is, taking into account the quorum sensing, the activity of arbutin, and the realization of biofilm by microbes. The behavior of microbes and the mode of action of certain phytomedicines overlap and allow through plant extracts to inhibit the diffusion mechanisms of microbes of the urinary tree. 相似文献
98.
99.
100.
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. 总被引:1,自引:0,他引:1
Chris H Takimoto Martin A Graham Graham Lockwood Chee M Ng Andrew Goetz Dennis Greenslade Scot C Remick Sunil Sharma Sridhar Mani Ramesh K Ramanathan Timothy W Synold James H Doroshow Anne Hamilton Daniel L Mulkerin Percy Ivy Merrill J Egorin Jean L Grem 《Clinical cancer research》2007,13(16):4832-4839
PURPOSE: To characterize the pharmacokinetics and pharmacodynamics of oxaliplatin in cancer patients with impaired renal function. EXPERIMENTAL DESIGN: Thirty-four patients were stratified by 24-h urinary creatinine clearance (CrCL) into four renal dysfunction groups: group A (control, CrCL, >or=60 mL/min), B (mild, CrCL, 40-59 mL/min), C (moderate, CrCL, 20-39 mL/min), and D (severe, CrCL, <20 mL/min). Patients were treated with 60 to 130 mg/m2 oxaliplatin infused over 2 h every 3 weeks. Pharmacokinetic monitoring of platinum in plasma, plasma ultrafiltrates, and urine was done during cycles 1 and 2. RESULTS: Plasma ultrafiltrate platinum clearance strongly correlated with CrCL (r2 = 0.712). Platinum elimination from plasma was triphasic, and maximal platinum concentrations (Cmax) were consistent across all renal impairment groups. However, only the beta-half-life was significantly prolonged by renal impairment, with values of 14.0 +/- 4.3, 20.3 +/- 17.7, 29.2 +/- 29.6, and 68.1 h in groups A, B, C, and D, respectively (P = 0.002). At a dose level of 130 mg/m2, the area under the concentration time curve increased in with the degree of renal impairment, with values of 16.4 +/- 5.03, 39.7 +/- 11.5, and 44.6 +/- 14.6 mug.h/mL, in groups A, B, and C, respectively. However, there was no increase in pharmacodynamic drug-related toxicities. Estimated CrCL using the Cockcroft-Gault method approximated the measured 24-h urinary CrCL (mean prediction error, -5.0 mL/min). CONCLUSIONS: Oxaliplatin pharmacokinetics are altered in patients with renal impairment, but a corresponding increase in oxaliplatin-related toxicities is not observed. 相似文献